Bruker (BRKR)

$58.63 -3.08% on the day Market cap $8.9B 52-week range $32.37 to $66.98 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
37% a year for 10 years

At a market value of $8.9B, Bruker's free cash flow of $43M (fiscal 2025) would need to grow about 37% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Bruker's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price36.6% a year
Free cash flow, last 9 years-8.2% a year
Revenue, same period8.8% a year
Price to free cash flow206.1x

Fundamental grade

D

Five factors scored 1 to 9 from BRKR's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation7
Profitability1
Growth2
Financial health4
Cash efficiency4

Key numbers

P/E (trailing)—
P/E (forward)—
Price / free cash flow—
EV / EBITDA—
Price / sales2.55x
Price / book—
Revenue growth+5.2%
Operating margin-0.87%
Net margin-2.0%
Return on equity-3.0%
Dividend yield—
Debt / equity1.52x

Results from SEC filings

Fiscal years, from Bruker's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$2.4B$2.5B$3.0B$3.4B$3.4B
Net income$277M$297M$427M$113M-$9M
Free cash flow$190M$145M$243M$136M$43M
EPS (diluted)$1.81$1.99$2.90$0.76-$0.15
Operating margin17.1%17.1%14.7%7.5%2.0%

Where the revenue comes from

Revenue by segments, fiscal 2025.

BSI CALID$1.2B35%
BSI NANO$1.1B32%
BSI BioSpin$879M26%
BEST$263M8%

Superinvestors who own BRKR

From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $149M0.05%Q2 2026
Andreas Halvorsen
Viking Global Investors
New position $54M0.15%Q2 2026
PRIMECAP Management
PRIMECAP Management Co
Added $53M0.03%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $30M0.07%Q2 2026
Larry Robbins
Glenview Capital Management
New position $15M0.28%Q2 2026

Insider buying

Open-market purchases by Bruker's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of BRKR in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when BRKR trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Bruker's stock price imply?

At a market value of $8.9B, Bruker would need its free cash flow to grow about 37% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew -8% a year.

Are Bruker insiders buying the stock?

No open-market insider purchases of BRKR in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Bruker?

5 of the superinvestors Investingly tracks hold BRKR in their latest 13F, including Cliff Asness, Andreas Halvorsen, PRIMECAP Management.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.